Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H23NO2 |
Molecular Weight | 261.3593 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2
InChI
InChIKey=DKLKMKYDWHYZTD-UHFFFAOYSA-N
InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3
Hexylcaine hydrochloride, a benzoic acid ester, is a local anaesthetic that has been used for surface anaesthesia of mucous membranes. Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01237a010 | https://www.google.ch/patents/US2486374
Curator's Comment: refrence retrieved from http://www.drugfuture.com/chemdata/hexylcaine-hydrochloride.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYCLAINE Approved UseHexylcaine hydrochloride, a benzoic acid ester, is a local anaesthetic that has been used for surface anaesthesia of mucous membranes.
Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
205 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/693515/ |
5 mL single, intrathecal dose: 5 mL route of administration: Intrathecal experiment type: SINGLE co-administered: |
HEXYLCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/693515/ |
5 mL single, intrathecal dose: 5 mL route of administration: Intrathecal experiment type: SINGLE co-administered: |
HEXYLCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
The clinical use of cyclaine (hexylcaine) as an anesthetic agent in urological surgery: a report of observations of 1000 patients. | 1954 Aug |
|
NEW AND nonofficial remedies: hexylcaine hydrochloride. | 1954 Jul 3 |
|
Topical anesthesia with hexylcaine (cyclaine) for major endoscopic procedures; evaluation and comparison in 1,732 administrations. | 1956 Apr 28 |
|
[Experience in the use of Osmocaine (hexylcaine) as a new local anesthetic in otorhinolaryngology]. | 1961 Nov |
|
A comparison in rat and mouse heart of the ability of several local anesthetics to inhibit monoamine oxidase. | 1983 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00473
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
HEXYLCAINE
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
274
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
100000083962
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
26879
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | RxNorm | ||
|
C004954
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
DTXSID1047863
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
7196
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
532-77-4
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
1373
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL1197
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
SUB08043MIG
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
511IU0826Z
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
10770
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY | |||
|
C65852
Created by
admin on Fri Dec 15 16:09:51 UTC 2023 , Edited by admin on Fri Dec 15 16:09:51 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)